Targeting PCSK9 to reduce residual risk in ACS
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Cardiology"
DOI: 10.1038/s41569-018-0125-6
Abstract: Patients who have had an acute coronary syndrome (ACS) are at high risk of recurrent cardiovascular events, particularly patients whose LDLcholesterol (LDLC) levels remain elevated despite receiving highintensity statin therapy. The ODYSSEY OUTCOMES trial now… read more here.
Keywords: risk; pcsk9 reduce; targeting pcsk9; pcsk9 ... See more keywords